Sponsored Links
| Jazz Pharmaceuticals Receives FDA Complete Response Letter Regarding JZP-6 For Treatment Of Fibromyalgia |
 |
 |
 |
| Medical News - Fibromyalgia | |||
|
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced that the U.S. Food and Drug Administration (FDA) has sent the company a complete response letter (CRL) regarding the company's New Drug Application (NDA) for JZP-6 (sodium oxybate) for the treatment of fibromyalgia. The CRL states that the FDA cannot approve the NDA in its present form... Read more: Fibromyalgia News From Medical News Today
|